Literature DB >> 1285067

Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.

P A Kemp1, J H Spragg, J C Brown, B P Morgan, C A Gunn, P W Taylor.   

Abstract

Murine monoclonal antibodies specific for neoepitopes expressed by C9 incorporated into membrane attack complexes and by membrane-bound C3b and iC3b have been prepared and characterised. These reagents were used to determine the extent and locus of complement activation in synovial-tissues obtained from patients with rheumatoid arthritis and osteoarthritis. In the four rheumatoid arthritis patients there was extensive deposition of C3 activation products and C5b-9 complexes onto the synovial membrane and the pattern of deposition of both neoantigens in serial tissue sections was very similar. There was less extensive staining for C3 and, particularly, C9 neoepitopes on the apical surface of vessel endothelia. In two of four osteoarthritic patients a similar pattern of C3 and C9 neoepitope deposition was found; in the remaining patients no C5b-9 could be located. Synovial vessel walls, but not synovial cells, from both groups of patients stained extensively for the complement regulatory protein CD59. In synovial membranes from patients with osteoarthritis, C9 appeared to be present predominantly in SC5b-9 complexes whereas in rheumatoid arthritis patients no evidence of S-protein incorporation into membrane attack complexes could be demonstrated, suggesting that in rheumatoid arthritis there is damage to the synovial membrane as a result of complement activation and C5b-9 deposition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285067

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  20 in total

1.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59.

Authors:  M Mizuno; K Nishikawa; B P Morgan; S Matsuo
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

3.  Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.

Authors:  Y T Konttinen; A Ceponis; S Meri; A Vuorikoski; P Kortekangas; T Sorsa; A Sukura; S Santavirta
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

4.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Authors:  A Familian; A E Voskuyl; G J van Mierlo; H A Heijst; J W R Twisk; B A C Dijkmans; C E Hack
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

5.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

6.  Tissue distribution of the rat analogue of decay-accelerating factor.

Authors:  O B Spiller; S M Hanna; B P Morgan
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

7.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

8.  Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2015 Jun-Jul       Impact factor: 4.565

9.  Complement factor H binds to denatured rather than to native pentameric C-reactive protein.

Authors:  Svetlana Hakobyan; Claire L Harris; Carmen W van den Berg; Maria Carmen Fernandez-Alonso; Elena Goicoechea de Jorge; Santiago Rodriguez de Cordoba; German Rivas; Palma Mangione; Mark B Pepys; B Paul Morgan
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

10.  Modulation of leukocyte recruitment and IL-8 expression by the membrane attack complex of complement (C5b-9) in a rabbit model of antigen-induced arthritis.

Authors:  Nicole L Tramontini; Paul J Kuipers; Colleen M Huber; Kerri Murphy; Keith B Naylor; Autumn J Broady; Kenneth S Kilgore
Journal:  Inflammation       Date:  2002-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.